Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Raya Therapeutic is a mission-driven biotech company focused on developing disease-modifying therapies for ALS and other neurodegenerative diseases. Its lead compound, fasudil (RT1968), has shown supportive clinical results in ALS patients. The company has reformulated fasudil to improve administration for patients with dysphagia and maintains a robust pipeline of five distinct clinical-stage compounds targeting different pathways relevant to motor neuron degeneration. Raya employs advanced selection techniques and is exploring combination therapies through strategic collaborations.[3][5][6]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Raya Therapeutic.